Plinabulin

About BeyondSpring Pharmaceuticals

BeyondSpring Pharmaceuticals is a clinical-stage oncology company developing its lead asset, Plinabulin, a first-in-class small-molecule immune modulator. The company's strategy is centered on demonstrating Plinabulin's efficacy in improving overall survival and reducing chemotherapy side effects, particularly in non-small cell lung cancer (NSCLC). With a late-stage pipeline and a leadership team experienced in oncology development, BeyondSpring aims to secure regulatory approvals and establish its therapies as new standards of care in key global markets.

Therapeutic Areas